Literature DB >> 29998355

Efficacy of Nd-YAG laser for treatment of pyogenic granuloma on the fingers and toes.

J Dong1, S G Peng1, X Y Zhang1, C G Tong1, F Liu1, M Cao1, Y H Li1, Y L He2.   

Abstract

Pyogenic granuloma (PG) is a common benign vascular proliferation which often occurs on the head, neck, hands, and feet. Among the various treatment options for PG, surgical excision is the most effective treatment which offers the lowest overall recurrence rates and also provides the exact diagnosis. However, it could have difficulties to do the surgery when lesions are located on the fingers and toes, especially very near to the nails, so laser may be a very good alternative choice. In this article, we evaluated the clinical efficacy and safety of neodymium-yttrium aluminum garnet (Nd:YAG) laser for treatment of PG located on the fingers and toes. Twenty-one patients with 21 PGs located on the fingers and toes were treated by multispot Nd-YAG laser. We chose monopulse (pulse width 10.5-13.5 ms; energy 100-125 J/cm2); treatment interval was 3-4 weeks. All lesions disappeared after one or two treatments. There was no apparent scar formation, no impact on the function of the fingers and toes, no damage to nail growth, and no recurrence in more than 12-month follow-up. Nd-YAG is an effective and safety treatment option for treatment of PG located on the fingers and toes.

Entities:  

Keywords:  Fingers; Nd-YAG laser; Pyogenic granuloma; Toes

Mesh:

Year:  2018        PMID: 29998355     DOI: 10.1007/s10103-018-2577-7

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  28 in total

1.  BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma.

Authors:  Leopold Groesser; Eva Peterhof; Matthias Evert; Michael Landthaler; Mark Berneburg; Christian Hafner
Journal:  J Invest Dermatol       Date:  2016-02       Impact factor: 8.551

2.  Treatment of pyogenic granulomas with the Nd-YAG laser.

Authors:  Raphael Bourguignon; Philippe Paquet; Claudine Piérard-Franchimont; Gerald E Piérard
Journal:  J Dermatolog Treat       Date:  2006       Impact factor: 3.359

3.  Treatment of lobular capillary hemangioma with the Nd:YAG laser: retrospective case series of 25 patients.

Authors:  Marie-Sophie Bédard; Jean Boulanger
Journal:  J Cutan Med Surg       Date:  2009 May-Jun       Impact factor: 2.092

Review 4.  Treatment options for cutaneous pyogenic granulomas: a review.

Authors:  James Lee; Hani Sinno; Youssef Tahiri; Mirko S Gilardino
Journal:  J Plast Reconstr Aesthet Surg       Date:  2011-02-11       Impact factor: 2.740

5.  Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients.

Authors:  B M Piraccini; A Alessandrini; E Dika; M Starace; A Patrizi; I Neri
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-02-23       Impact factor: 6.166

6.  Is timolol an effective treatment for pyogenic granuloma?

Authors:  Divya Gupta; Nidhi Singh; Devinder Mohan Thappa
Journal:  Int J Dermatol       Date:  2016-02-12       Impact factor: 2.736

7.  Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases.

Authors:  S J Patrice; K Wiss; J B Mulliken
Journal:  Pediatr Dermatol       Date:  1991-12       Impact factor: 1.588

8.  Pyogenic granuloma in children.

Authors:  Kelley A Pagliai; Bernard A Cohen
Journal:  Pediatr Dermatol       Date:  2004 Jan-Feb       Impact factor: 1.588

9.  Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report.

Authors:  Juan Liu; Bing-Rong Zhou; Fei Yi; Hong-Jin Wu; Jia-An Zhang; Dan Luo
Journal:  Exp Ther Med       Date:  2015-11-27       Impact factor: 2.447

Review 10.  Dermoscopy, confocal laser microscopy, and hi-tech evaluation of vascular skin lesions: diagnostic and therapeutic perspectives.

Authors:  Marta Grazzini; Ignazio Stanganelli; Susanna Rossari; Alessia Gori; Teresa Oranges; Anna Sara Longo; Torello Lotti; Pier Luca Bencini; Vincenzo De Giorgi
Journal:  Dermatol Ther       Date:  2012 Jul-Aug       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.